Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance
(2013) American Journal of Clinical Pathology — Vol. 140, n° 4, p. 561-566 (2013)
Files
2013_Lambein_Am_J_Clin_Pathol.pdf
Restricted Access - Adobe PDF
- 366.11 KB
Details
- Authors
- Abstract
- OBJECTIVES: To investigate the clinical and pathobiological significance of distinguishing score 0 and score 1+ within the group of immunohistochemistry (IHC)-negative invasive breast cancers. METHODS: We studied HER2 status using both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast tumors submitted to our laboratory after a negative IHC result in local testing centers. RESULTS: We were able to discern a group of score 0 tumors that had a lower HER2 copy number than the group consisting of score 1+ tumors. In contrast with the group of score 1+ tumors, HER2 FISH was consistently negative for both copy number-based and ratio-based tumors without equivocal results. CONCLUSIONS: In a setting with stringent quality assurance, score 0 and score 1+ tumors emerge as distinct and clinically important subgroups within the HER2 IHC-negative population
- Affiliations
Ghent University Hospital Department of Pathology
Citations
Lambein, K., Van Bockstal, M., Vandemaele, L., Geenen, S., Rottiers, I., Nuyts, A., Matthys, B., Praet, M., Denys, H., & Libbrecht, L. (2013). Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. American Journal of Clinical Pathology, 140(4), 561-566. https://doi.org/10.1309/AJCP4A7KTAYHZSOE (Original work published 2013)